Last reviewed · How we verify
ARD6562, Docetaxel
ARD6562, Docetaxel, is a microtubule inhibitor that disrupts cell division.
ARD6562, Docetaxel, is a microtubule inhibitor that disrupts cell division. Used for Breast cancer, Non-small cell lung cancer, Prostate cancer.
At a glance
| Generic name | ARD6562, Docetaxel |
|---|---|
| Sponsor | Sanofi |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Docetaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. This leads to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Approved indications
- Breast cancer
- Non-small cell lung cancer
- Prostate cancer
Common side effects
- Neutropenia
- Fatigue
- Anemia
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |